Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: ISRG.NASDAQ
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Intuitive Surgical (ISRG) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

BUY

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

NEUTRAL

$432

+9.7%

2031

5-Year

BUY

$663

+68.6%

Published batch insight

Robotic Surgical Monopoly Confronts Hospital Capital Rationing And Margin Concessions

There is high consensus that non-discretionary surgical procedure volumes and recurring consumable sales insulate cash generation from macroeconomic volatility. However, sharp divergence exists regarding valuation durability, as elevated interest rates, operating-lease mix shifts, and arriving multiport competition threaten long-term profit margins.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Machiavelli (Insider), Superintelligence (Anthropologist), Universal Investor (Polymath), Sherlock Holmes (Whistleblower), Michael Burry (Vulture), Warren Buffett (Value Purist), Elon Musk (Visionary), Ray Dalio (Strategist), J.P. Morgan (Titan). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Intuitive Surgical at the forecast anchor (2026-09-18): $16,857 in five years versus $13,892 for S&P 500 benchmark.

Intuitive Surgical · Synthesized ConsensusS&P 500 benchmark

Figure: Five-year synthesized consensus value path for Intuitive Surgical compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 393.33 USD1-year price return: +9.72%5-year price return: +68.57%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter	Target (USD)	Quarter return	Total return	Forecast rationale
Q4 2026	399.38	+1.54%	+1.54%	Year-end procedure volume resilience and initial da Vinci 5 commercial shipments counter restrictive monetary policy headwinds, allowing high-margin instrument turnover to support modest valuation stabilization.
Q1 2027	407.03	+1.92%	+3.48%	Fiscal 2027 guidance introduces conservative revenue-per-procedure assumptions from the extended-use instrument rollout and hospital capex freezes, prompting estimate recalibration and mild multiple compression.
Q2 2027	421.20	+3.48%	+7.09%	First-quarter procedure data confirms that underlying surgical volume growth remains durable above fourteen percent, while European regulatory momentum cushions domestic capital equipment procurement delays.
Q3 2027	431.58	+2.46%	+9.72%	Summer surgical seasonality moderates procedural turnover, but progressive adoption of force-feedback instrumentation and steady share repurchases maintain predictable per-share cash-flow compounding.
Q4 2027	449.64	+4.19%	+14.32%	Hospital fiscal year-end budget flushes drive a seasonal inflection in multiport replacements, lifting fourth-quarter console shipments and validating operating margin resilience above thirty percent.
Q1 2028	457.84	+1.82%	+16.40%	Rival commercial launches introduce competitive tender friction and pricing scrutiny, yet surgeon switching inertia and established clinical workflows prevent meaningful customer defection.
Q2 2028	469.50	+2.55%	+19.36%	Manufacturing scale on fifth-generation components reduces unit costs, absorbing instrument pricing concessions and driving healthy operating cash-flow conversion across expanded clinical indications.
Q3 2028	483.15	+2.91%	+22.84%	Recurring consumable replenishment across academic and community hospitals buffers seasonal procedure moderation, preserving solid free cash flow generation despite persistent high borrowing benchmarks.
Q4 2028	501.85	+3.87%	+27.59%	Year-end fleet upgrades accelerate as hospital networks standardize on advanced computational consoles, propelling annual operating cash flow and funding continued programmatic equity retirements.
Q1 2029	515.37	+2.69%	+31.03%	First-quarter procedural volumes maintain steady low-teens expansion, led by general surgery and thoracic indications, while leasing collections provide highly visible recurring cash streams.
Q2 2029	531.02	+3.04%	+35.01%	Early commercialization of digital surgical analytics and simulation subscriptions begins adding high-margin recurring software revenue, supporting steady incremental operating margin expansion.
Q3 2029	544.64	+2.56%	+38.47%	International procedure expansion across Europe and developed Asia compensates for domestic market maturation, maintaining overall revenue momentum despite competitive pressure in secondary markets.
Q4 2029	564.01	+3.56%	+43.39%	Robust fourth-quarter capital installations and record consumable shipments drive strong annual cash conversion, cementing the platform's role as an indispensable surgical utility.
Q1 2030	575.08	+1.96%	+46.21%	Demographic aging continues to expand non-discretionary oncology and pelvic floor caseloads, providing a predictable procedural floor that shields earnings from broader late-cycle macroeconomic deceleration.
Q2 2030	586.68	+2.02%	+49.16%	Expanded regulatory clearances for outpatient ambulatory surgery center applications broaden the accessible procedure pool, sustaining healthy instrument pull-through per installed console.
Q3 2030	601.46	+2.52%	+52.91%	Installed base scale exceeding fourteen thousand systems generates an unshakeable consumable toll, neutralizing seasonal elective procedure dips and preserving fortress balance sheet liquidity.
Q4 2030	619.67	+3.03%	+57.54%	Solid fiscal year-end console placements and expanding software integration generate superior cash conversion, enabling management to execute steady accretive share repurchases.
Q1 2031	631.55	+1.92%	+60.56%	Normalized low-teens procedural growth establishes a mature compounding cadence, where earnings expansion drives equity appreciation while terminal valuation multiples settle near historical medtech averages.
Q2 2031	648.68	+2.71%	+64.92%	Advanced endoscopic platforms and single-port applications deepen hospital workflow entrenchment, generating steady high-margin consumable turnover across diverse surgical specialties.
Q3 2031	663.04	+2.21%	+68.57%	The forecast period concludes with undisputed robotic ecosystem leadership, where massive procedural cash generation and pristine balance-sheet strength cement durable through-cycle shareholder returns.

The base-case investment thesis balances secular surgical robotics adoption against structural multiple compression in a restrictive interest-rate regime. Intuitive Surgical's economic engine is anchored by an installed base exceeding 11,700 systems, generating over 80% recurring revenue through proprietary instruments, accessories, and service contracts. This razor-and-blade model decouples cash generation from lumpy hospital capital expenditure cycles. However, valuation sensitivity remains acute. At 45x trailing earnings, the equity functions as a long-duration asset vulnerable to discount-rate pressure and hospital capital rationing. Furthermore, self-inflicted price concessions via the 2027 Extended Use Program, alongside the arrival of cleared competitors, will decouple revenue growth from procedure volume.

Key insights

Operating lease migration preserves installed-base placement velocity but lengthens cash payback periods and dilutes upfront revenue recognition across hospital networks.
Extended-use instrument programs pre-emptively defend market share against emerging modular competitors but cap medium-term consolidated gross margin expansion below 68%.
Free cash flow conversion exceeding 100% of net income funds continuous share repurchases, transforming operational compounding into per-share equity accretion.

Deep Dive

Prevailing market consensus views Intuitive Surgical as an elite medtech compounder whose da Vinci 5 rollout ensures uninterrupted mid-teens procedural compounding. Investors treat the razor-and-blade consumable model as largely impervious to broader economic headwinds. However, media commentary and sell-side price target reductions reflect growing anxiety that elevated sovereign bond yields, post-pandemic procedure normalization, and arriving soft-tissue competition from multinational healthcare conglomerates will permanently cap valuation multiples.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd modestly underestimates Intuitive's valuation durability, but overestimates the near-term velocity of outright hardware capital sales. The market fixates on quarterly console delivery optics, overlooking that recurring instruments and services generate over 80% of turnover. However, consensus models also ignore the 2027 Extended Use Program, which voluntarily surrenders instrument pricing per procedure to lock out competitors. This creates a nuanced alpha gap: operational compounding is more resilient than feared, but gross margins face a structural ceiling.

Repricing catalyst

Upcoming financial reporting through fiscal 2027 will resolve the gap between headline capital equipment concerns and procedural cash durability. The critical trigger will be reported gross margin stability near 68% and sustained mid-teens recurring consumable revenue expansion as da Vinci 5 utilization deepens. Confirmation that instrument pull-through outpaces hardware placement lumpiness will compel institutional asset allocators to reprice the shares based on resilient through-cycle cash flows.

Published consensus context

Macro regime alignment

The prevailing monetary regime of elevated policy rates and restrictive sovereign yields presents a clear headwind for hospital debt financing and equity duration multiples. However, surgical procedure demand exhibits near-zero elasticity to macroeconomic cycles. Intuitive's zero-debt fortress balance sheet, substantial net cash reserves, and self-funded capital deployment insulate operations, transforming external credit constraints into a relative competitive moat against levered medtech rivals.

Published consensus context

Advisor disagreement

The primary debate across reports concerns terminal valuation multiples and the durability of pricing power. Bullish analyses assume that procedural compounding and surgeon residency lock-in will preserve a premium multiple above 40x earnings, arguing that competitor platforms will remain irrelevant. Conversely, cautious perspectives emphasize that 5% bond yields fundamentally re-rate growth equities, while the commercial arrival of Medtronic's Hugo and J&J's Ottava arms hospital procurement committees with bargaining leverage. Furthermore, reports disagree on whether the 2027 Extended Use Program represents a margin-diluting price concession or an unassailable defensive moat that accelerates customer volume.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Recurring Consumables Tollbooth Compounding: Proprietary instruments, specialized accessories, and multi-year service contracts generate over 80% of total revenue. As worldwide surgical procedures expand at 14% to 16% annually across general surgery, thoracic, and colorectal indications, recurring consumable turnover compounds automatically. This procedure-linked tollbooth shields cash generation from hospital capital expenditure freezes, ensuring predictable double-digit operational cash flows across macroeconomic cycles. Expected impact: +28%.
Fifth-Generation Platform Upgrade Supercycle: The commercial deployment of da Vinci 5 drives a multi-year hardware replacement cycle across an installed base exceeding 11,700 systems. Featuring force-feedback sensing, tenfold computational processing capability, and 11% higher procedural throughput, the console compels health networks to upgrade aging fleets. This platform refresh commands premium average selling prices and locks in multi-year service contracts. Expected impact: +24%.
Global Demographic Minimally Invasive Migration: Aging populations across North America, Europe, and developed Asia structurally drive incidence curves in oncological, urological, and soft-tissue pathologies. Concurrently, hospital administrators prioritize robotic minimally invasive interventions to shorten inpatient hospital stays and lower surgical complication rates. This clinical necessity expands procedure volumes and drives geographic penetration across under-indexed international healthcare delivery systems. Expected impact: +18%.
Fortress Balance Sheet Self-Funded Buybacks: Intuitive generates trailing free cash flow exceeding $3.2 billion with zero gross debt and over $8.6 billion in liquid reserves. Having completed major manufacturing facility expansions, capital expenditure intensity has normalized near 5% of revenue. Management redeploys surplus cash into programmatic share repurchases, systematically retiring equity float and accreting per-share earnings without relying on debt markets. Expected impact: +14%.

Top frictions and headwinds

Restrictive Cost of Capital Compression: Sovereign bond yields near 5.0% and central bank policy rates around 4.0% impose persistent discount-rate gravity on long-duration healthcare growth equities. Intuitive's trailing price-to-earnings multiple of 45x faces structural resistance against returning to historical peak multiples. This macroeconomic constraint forces shareholder returns to track underlying operational earnings compounding rather than multiple re-expansion. Expected impact: -17%.
Hospital Capital Freezes and Leasing Shift: Healthcare systems facing labor cost inflation and tight operating margins are increasingly deferring outright multimillion-dollar console purchases. Instead, hospitals demand operating leases and usage-based financing. While leasing preserves long-term placement volume, it defers upfront hardware revenue recognition, increases Intuitive's balance-sheet asset commitments, and modestly dampens near-term return on invested capital. Expected impact: -13%.
Cleared Multiport Competitor Tender Encroachment: Regulatory clearances for Medtronic's Hugo and Johnson & Johnson's Ottava platforms formally end Intuitive's absolute domestic monopoly in soft-tissue robotics. While clinical switching barriers and surgeon training remain formidable moats, hospital procurement committees exploit competing platforms to demand instrument bundle discounts and favorable trade-in terms, exerting downward pressure on hardware pricing. Expected impact: -11%.
Extended-Use Pricing and Procurement Concessions: The scheduled rollout of extended-use instruments in 2027 deliberately lowers customer cost-per-procedure in high-volume benign surgeries to deny rivals a market opening. However, this self-inflicted concession decouples instrument revenue growth from underlying procedure expansion. Combined with international volume-based procurement pressures, this dynamic establishes an observable near-term ceiling on gross margin expansion. Expected impact: -9%.

Tail risks

Federal Robotic Procedural Reimbursement Carve-Out: Mounting healthcare entitlement deficits could prompt CMS to enact restrictive bundled payments or site-neutral caps that eliminate premium reimbursement for robotic-assisted laparoscopic surgery by 2028. Lacking financial incentives in routine hernia or gallbladder repairs, hospitals would curtail robotic consumable utilization, reducing procedure growth to single digits and compressing gross margins. Probability: +22%. Expected impact: -28%.
Catastrophic Systemic Sensor Recall Event: A critical defect in da Vinci 5's force-feedback sensor architecture or an algorithmic firmware flaw leading to intraoperative vascular complications could trigger a mandatory FDA Class I recall. Regulators would halt console shipments and suspend surgical procedures pending retrofits, inflicting massive remediation costs, litigation liabilities, and severe reputational damage. Probability: +14%. Expected impact: -34%.

Tail opportunities

Autonomous Surgical Guidance Regulatory Breakthrough: Regulators could grant breakthrough clearance by 2028 for real-time intraoperative AI surgical guidance and automated suturing sub-tasks on da Vinci 5. This would transform the console from a tele-manipulator into an active clinical assistant, unlocking recurring enterprise software subscriptions of over $150,000 annually per system and expanding gross margins beyond 72%. Probability: +28%. Expected impact: +32%.
Universal Outpatient Ambulatory Surgical Penetration: A coordinated overhaul by CMS and commercial payers establishing enhanced, site-neutral procedural reimbursement parity by 2027 would accelerate robotic adoption in ambulatory surgery centers. Intuitive's compact single-port and da Vinci 5 variants would rapidly penetrate outpatient facilities, doubling addressable domestic surgical volume and expanding consumable sales beyond 22% annually. Probability: +32%. Expected impact: +25%.

What to monitor

Thesis watchpoints

-- Confirmation: Quarterly global procedure growth sustaining above 15% year-over-year through mid-2027 verifies resilient biological demand and recurring instrument pull-through.

Key insights

Deterioration: Consolidated gross margins dropping below 65% across two consecutive quarters signals unabsorbed supply-chain inflation or aggressive competitor-driven price discounting.
Reassessment: Cumulative US installed base for Hugo or Ottava exceeding 500 units by late 2028 warrants fundamental re-underwriting of pricing power.

Company Financial Analysis

Intuitive Surgical Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

Intuitive's financial performance demonstrates an exceptional compounding engine driven by non-discretionary patient procedures. Trailing twelve-month revenue reached $11.03 billion by mid-2026, supported by robust 18.5% year-over-year growth in the second quarter. Net income advanced to $3.14 billion, propelled by double-digit procedure growth and expanding demand for the da Vinci 5 system. Crucially, recurring sales of single-use instruments, accessories, and maintenance contracts now represent over 80% of total turnover, insulating top-line performance from cyclical healthcare slowdowns. The real strength of this business lies in its remarkable cash generation. Trailing free cash flow reached $3.22 billion, converting net income into cash at a rate exceeding 100%. This highlights an essential procedural utility whose cash generation remains completely self-funding.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 10.1B	USD 2.9B	USD 2.5B
2024	USD 8.4B	USD 2.3B	USD 1.3B
2023	USD 7.1B	USD 1.8B	USD 749.6M
2022	USD 6.2B	USD 1.3B	USD 958.4M
2021	USD 5.7B	USD 1.7B	USD 1.7B

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	71.5x	TTM	Native	USD / USD
2024	81.8x	TTM	Native	USD / USD
2023	67.2x	TTM	Native	USD / USD
2022	71.6x	Annual	Native	USD / USD
2021	77.4x	Annual	Native	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Operating profitability exhibits structural resilience anchored by high-margin consumable instrument sales. Gross margin held stable at 66.0% in fiscal 2025, while operating margin expanded to 29.3%, reaching 31.3% on a trailing twelve-month basis by mid-2026. This operational leverage shows that steady procedural volume growth and administrative cost control easily absorbed early manufacturing startup expenses for the da Vinci 5 console. The underlying story is driven by a highly favorable product mix. Recurring instruments and services generate gross margins near 70%, offsetting the introductory overhead of building advanced robotic consoles. As manufacturing efficiencies for new sensors mature, fixed factory costs will spread across higher unit volumes, structurally protecting operating margins despite competitive market pressures.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD 2.9B	29.3%	28.4%
2024	USD 2.3B	28.1%	27.8%
2023	USD 1.8B	24.8%	25.2%
2022	USD 1.6B	25.3%	21.3%
2021	USD 1.8B	31.9%	29.9%

Balance sheet and leverage

AI Review

Intuitive maintains a classic fortress balance sheet engineered for complete strategic independence. The company operates with zero long-term funded debt, carrying a debt-to-equity ratio of just 0.02 that reflects only standard operating leases. With total stockholders' equity of $17.82 billion, a current ratio of 4.87, and over $8.6 billion in cash and liquid investments, the business faces no debt refinancing risks in a high-interest-rate world. This liquidity buffer provides vital strategic flexibility. While financially strained hospital customers navigate higher borrowing benchmarks, Intuitive can comfortably offer flexible equipment leasing structures directly from its own reserves. Furthermore, management can opportunistically deploy billions into share repurchases during broader market downturns without compromising its intensive research programs.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 302.8M	USD 5.9B	USD 3.1B net cash	4.87x
2024	USD 146M	USD 4B	USD 1.9B net cash	4.07x
2023	USD 89.8M	USD 5.2B	USD 2.8B net cash	4.76x
2022	USD 93.8M	USD 4.1B	USD 1.6B net cash	4.40x
2021	USD 87M	USD 4.2B	USD 1.2B net cash	5.08x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management has transitioned capital spending from heavy infrastructure construction into operational cash harvesting. After committing between 13% and 15% of revenue to facility buildouts during 2023 and 2024 to support fifth-generation manufacturing, capital expenditures moderated to 5.4% of revenue in fiscal 2025. This planned reduction released substantial cash flow without constraining production capacity, leaving the business with ample manufacturing headroom to support global platform rollouts. Meanwhile, internal investment remains firmly focused on technological leadership, with research and development spending climbing to $1.31 billion in 2025. By funding proprietary force-sensing instruments and computational software out of internally generated cash flow, Intuitive expands its competitive lead while keeping its operations highly capital-efficient.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 539.8M	USD 1.3B
2024	USD 1.1B	USD 1.1B
2023	USD 1.1B	USD 998.8M
2022	USD 532.4M	USD 879M
2021	USD 353.5M	USD 671M

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	NEUTRAL	113	+10.7%	Not available	ORIGINAL
5Y	BUY	146	+76.3%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	377.6	402.04	413	14
+6M	March 18, 2027	388.92	410.89	429.52	14
+9M	June 18, 2027	393.21	424.77	455.29	14
+1Y	September 18, 2027	385.35	435.43	468.95	14
+15M	December 18, 2027	393.05	454.23	492.39	14
+18M	March 18, 2028	396.98	463.94	512.09	14
+21M	June 18, 2028	404.92	479.6	542.81	14
+2Y	September 18, 2028	408.97	491.61	559.1	14
+27M	December 18, 2028	417.15	511.55	587.05	14
+30M	March 18, 2029	421.32	525.76	610.54	14
+33M	June 18, 2029	429.75	543.82	641.06	14
+3Y	September 18, 2029	434.05	557.74	660.29	14
+39M	December 18, 2029	442.73	578.86	693.31	14
+42M	March 18, 2030	447.16	591.4	721.04	14
+45M	June 18, 2030	456.1	608.77	757.09	14
+4Y	September 18, 2030	460.66	623.6	779.81	14
+51M	December 18, 2030	469.87	644.23	811	14
+54M	March 18, 2031	469.87	657.27	835.33	14
+57M	June 18, 2031	479.27	677.28	877.1	14
+5Y	September 18, 2031	484.06	693.44	912.18	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

The Value Seeker

Gemini 3.8 Flash

Weight5.6/100

Prudent examination of razor-and-blade economics and da Vinci 5 throughput advantages. Accurately models share repurchase accretion, but projects a relatively benign path that overlooks near-term extended-use pricing concessions.

AI RESEARCHER

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

Weight4.6/100

Offers valuable institutional analysis regarding surgeon training capture and residency lock-in. Nevertheless, projects aggressive terminal multiple expansion to fifty-two times earnings that contradicts prevailing macroeconomic tightening and capital rationing pressures.

AI RESEARCHER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight4.6/100

Synthesizes data telemetry and hospital negentropy advantages well, but projects an elevated terminal multiple of thirty-six times earnings alongside fifty-percent revenue expansion that underestimates public single-payer healthcare budgetary caps.

AI RESEARCHER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight3.7/100

Presents an aggressive multiple expansion scenario that underestimates duration headwinds in a restrictive interest-rate environment. While correctly assessing recurring revenue density, assuming multiple expansion past forty times earnings under five-percent bond yields lacks macroeconomic consistency.

AI RESEARCHER

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

Weight2.8/100

Heavily overweighted toward an imperial monopoly thesis that dismisses rival regulatory approvals too readily. Projects overly optimistic price returns without sufficiently accounting for hospital procurement committee leverage and long-duration equity multiple compression.

Skip to references

Research Provenance

References & Context

This Intuitive Surgical consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 67 deduplicated sources retained for this batch.

01Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
02https://www.sec.gov/Archives/edgar/data/1035267/000103526726000047/q226ex-991earningsrelease.htm?utm_source=openaisec.gov
03INTUITIVE SURGICAL INC - Form 8-K - FY2026sec.gov
04isrg-20251231sec.gov
05isrg-20260630sec.gov
06www.sec.govsec.gov
07ISRG Stock Sinks as Analysts Cut Price Targets on Intuitive Surgicalbarchart.com
082027 trends to watch: Coverage losses will challenge healthcare growth strategiesdefinitivehc.com
09Intuitive Announces Second Quarter Earningsfinance.yahoo.com
10Intuitive Surgical, Inc. Q2 2026 Earnings Call Summaryfinance.yahoo.com
11Intuitive Surgical (ISRG) Stock Has Plunged 33% in 2026. Here's Why One Fund Manager Remains Bullish -- and Why I Do, Too. | The Motley Foolfool.com
12Earnings call transcript: Intuitive Surgical beats Q2 2026 estimates, shares fall By Investing.cominvesting.com
13Da Vinci 5 Cleared for Cardiac Procedures | Intuitive Surgicalisrg.intuitive.com
14Intuitive Announces First Quarter Earnings | Intuitive Surgicalisrg.intuitive.com
15Intuitive Announces Fourth Quarter Earnings | Intuitive Surgicalisrg.intuitive.com

And 52 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.